Microbatteries: microscopic in size, but with gigantic ambitions
Imagine a battery as thin as a human hair and as long as a quarter of a grain of rice. This is the feat achieved by this startup, which is developing solid lithium‑ion microbatteries intended for medical implants. Their commitment is to offer a reliable energy source, which is wirelessly rechargeable, for medical monitoring devices implanted directly in the human body.
These batteries are designed to meet very specific needs, such as the continuous monitoring of complex diseases, including:
- Glaucoma: The batteries can measure eye pressure non‑invasively.
- Cardiac and neurological problems: They can monitor the patient’s condition in real time, without resorting to invasive treatment.
- Hydrocephalus: They add unprecedented precision to diagnosis and monitoring.
Strategic fundraising for a long‑term vision
Injectpower has just reached a decisive milestone, with fundraising of €6.5 million, thanks to renowned investors, particularly in real estate and technologies. This sum will make it possible to finalize R&D and begin industrial production, which is planned for 2025.
However, this is only one step. The business is aiming to raise additional funds, estimated to be between €40 and €50 million in 2024. The aim is to build a factory near Grenoble, a unique production site designed around micro‑electromechanical systems (MEMS) technologies.
Why stop at technological innovation when we can also revolutionize production? The startup plans to use 200mm silicon wafers, which feature in microelectronics, to produce its batteries on a large scale.
One wafer would make it possible to manufacture 10,000 microbatteries, with reliability and efficiency standards inherited from microelectronics processes. This strategic choice ensures rapid ramp‑up and cost optimization, while preserving impeccable quality.
With a global medical implant market estimated at US$103 billion in 2022, the startup is initially focusing on France and the United States, but also plans to target the European Union.
Marketing is planned for the end of 2025, or the beginning of 2026, an ambitious but realistic trajectory, given the expertise accumulated by the team and its network of investors.
With Injectpower, Grenoble continues to shine as a hub dedicated to technology and healthcare. By combining local scientific excellence, cutting‑edge industrial expertise and a clear vision of medical needs, the startup has established itself as a key player in the MedTech industry.